Article Sidebar

Submitted
November 6, 2024
Accepted
November 6, 2024
Published
November 6, 2024
Download
PDF
Statistic
Read Counter : 482 Download : 305

Main Article Content

Abstract

Background and Objectives: Masseter hypertrophy (MH) is characterized by abnormal
enlargement of the masseter muscle (MM), leading to aesthetic concerns and functional
impairment. This study aimed to evaluate the clinical efficacy and safety of botulinum toxin type
A (BTX-A) injections for the reduction of masseter muscle hypertrophy (MMH).
Methods: A prospective clinical study was carried out in the Maxillofacial Department of
Rizgary Teaching Hospital from February 2018 to August 2019 and 19 patients were included
who were suffering from MH. The condition was clinically diagnosed. With the diluted BTX
A (30IU in ringer lactates injected at five masseter points, 6 iu each points ), Pre-injection and
post-injection performance measurements were performed at 12 weeks on a patient-self-reported
scale using a visual analog scale (VAS).
Results: This study's findings indicate that 12 weeks after the administration of BTX-A, there
was a significant efficacy in reducing MMH, with only one patient exhibiting no change in
muscle hypertrophy post-injection but after injection was reduced and one patient . exhibit
herniation
Conclusion: This study established that the use of BTX-A significantly decreased MMH.
These results suggest that BTX-A can be utilized as a safe and risk-free method with maximum
effectiveness in treating MMH.

Keywords

Botulinum Toxin Hypertrophy Masseter Hypertrophy Visual Analogue Scale

Article Details

License

Copyright (c) 2024 University of Thi-Qar Journal Of Medicine

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

References

  1. Mattsson J, Carlsson A. Masseter and temporalis muscle thickness as assessed by ultrasound–a
  2. proof-of-concept study.
  3. Almukhtar RM, Fabi SG. The masseter muscle and its role in facial contouring, aging, and
  4. quality of life: a literature review. Plastic and Reconstructive Surgery. 2019 Jan 1;143(1):39e
  5. e.
  6. Pinto AS, GalvÃo ND, Mendes JD, Pinto PH, Lopes SL, Costa AL. Evaluation measure of 3d
  7. volumetry of masseter hypertrophy: association with modalities of imaging. RGO-Revista
  8. Gaúcha de Odontologia. 2018 Oct;66:375-83.
  9. Beaumont S, Garg K, Gokhale A, Heaphy N. Temporomandibular disorder: a practical guide
  10. for dental practitioners in diagnosis and management. Australian Dental Journal. 2020
  11. Sep;65(3):172-80.
  12. Haun CT, Vann CG, Roberts BM, Vigotsky AD, Schoenfeld BJ, Roberts MD. A critical
  13. evaluation of the biological construct skeletal muscle hypertrophy: size matters but so does the
  14. measurement. Frontiers in physiology. 2019 Mar 12;10:247.
  15. Anehosur V, Mehra A, Kumar N. Management of masseter muscle hypertrophy and role of
  16. adjunctive surgical procedures. Craniomaxillofacial Trauma & Reconstruction Open. 2020 Apr
  17. ;5:2472751220913147.
  18. Castroflorio T, Bargellini A, Deregibus A, Svensson P. Masticatory muscle pain and
  19. disorders. InContemporary Oral Medicine 2018 Dec 26 (pp. 1-38). Springer Nature Switzerland
  20. AG 2018.
  21. Arora A, Sodhi A, Hegde S, Roy AK. Masseter muscle hypertrophy associated with
  22. temporomandibular joint disorder-A case report. Am J Oral Med Radiol. 2015;2(3):110-4.
  23. Caldas W, Conti AC, Janson G, Conti PC. Occlusal changes secondary to temporomandibular
  24. joint conditions: a critical review and implications for clinical practice. Journal of Applied Oral
  25. Science. 2016;24(4):411-9.
  26. Ayhan M, İşler SC, Kasapoglu C. Combination of medical and surgical treatments for
  27. masseter hypertrophy. Case Reports in Dentistry. 2018;2018(1):7168472.
  28. Lee EI, Kim NH, Park RH, Park JB, Ahn TJ. Botulinum Toxin Type A for Treatment of
  29. Masseter Hypertrophy: Volumetric Analysis of Masseter Muscle Reduction over Time. Archives
  30. of Aesthetic Plastic Surgery. 2016 Jul 8;22(2):79-86.
  31. Kahn A, Bertin H, Corre P, Praud M, Paré A, Kün-Darbois JD. Assessing the effectiveness
  32. of botulinum toxin injections into masticatory muscles in the treatment of temporomandibular
  33. disorders. Journal of Oral Medicine and Oral Surgery. 2018 Oct 1;24(3):107-11.
  34. Wei J, Xu H, Dong J, Li Q, Dai C. Prolonging the duration of masseter muscle reduction by
  35. adjusting the masticatory movements after the treatment of masseter muscle hypertrophy with
  36. botulinum toxin type a injection. Dermatologic Surgery. 2015 Jan 1;41:S101-9.
  37. Kim NH, Park RH, Park JB. Botulinum toxin type A for the treatment of hypertrophy of the
  38. masseter muscle. Plastic and reconstructive surgery. 2010 Jun 1;125(6):1693-705.
  39. Novembre D, Ferragina F, Cordaro R, Cristofaro MG. Efficacy of botulinum toxin type a in
  40. bilateral hypertrophy of masseter and temporalis muscles. A case report. POLICLINICO.
  41. SEZIONE MEDICA. 2020;127(1):1-9.
  42. Mor N, Tang C, Blitzer A. Temporomandibular myofacial pain treated with botulinum toxin
  43. injection. Toxins. 2015 Jul 24;7(8):2791-800.
  44. Satriyasa BK. Botulinum toxin (Botox) A for reducing the appearance of facial wrinkles: a
  45. literature review of clinical use and pharmacological aspect. Clinical, cosmetic and
  46. investigational dermatology. 2019 Apr 10:223-8.
  47. Tater P, Pandey S. Botulinum toxin in movement disorders. Neurology India. 2018 Mar
  48. ;66(Suppl 1):S79-89.
  49. Klein FH, Brenner FM, Sato MS, Robert FM, Helmer KA. Lower facial remodeling with
  50. botulinum toxin type A for the treatment of masseter hypertrophy. Anais brasileiros de
  51. dermatologia. 2014 Nov;89:878-84.
  52. Cheng J, Hsu SH, McGee JS. Botulinum toxin injections for masseter reduction in East
  53. Asians. Dermatologic Surgery. 2019 Apr 1;45(4):566-72.
  54. Yeh YT, Peng JH, Peng HL. Literature review of the adverse events associated with
  55. botulinum toxin injection for the masseter muscle hypertrophy. Journal of cosmetic dermatology.
  56. Oct;17(5):675-87.
  57. Tsai CY, Lei YY, Yang LY, Chiu WC. Changes of masseter muscle activity following
  58. injection of botulinum toxin type A in adult rats. Orthodontics & Craniofacial Research. 2015
  59. Nov;18(4):202-11.
  60. Peng HL, Peng JH. Complications of botulinum toxin injection for masseter hypertrophy:
  61. Incidence rate from 2036 treatments and summary of causes and preventions. Journal of
  62. cosmetic dermatology. 2018 Feb;17(1):33-8.

Similar Articles

You may also start an advanced similarity search for this article.